https://www.avient.com/sites/default/files/2020-12/automotive-ir-lens-of-sensor-case-study-brief.pdf
FAMOUS TIER 2
COMPANY
A U T O M O T I V E L I G H T I N G
I R L E N S O F S E N S O R
• High heat resistance up to 203°C
• PESU base resin with high IR transmission
• Visible light cannot pass through
• Used rich experience with different IR
transmission materials to support
customer’s material design and test method
• Customized color for IR transmittance,
which allowed IR to pass through the plastic
lamp without accumulating high heat
Edgetek™ ET9400-8005 IR Formulation
KEY REQUIREMENTS
WHY AVIENT?
https://www.avient.com/sites/default/files/2024-02/Transcend - Tibial Trials Case Study Snapshot.pdf
S U RG I C A L
I N S T RU M E N T O E M
T I B I A L T R I A L S
• Offered in various colors for ease of brand identification
and sizing differentiation
• Able to withstand repeated steam sterilization and
chemical disinfection
• Available in low minimum order quantities (MOQ)
• Delivered a variety of bright, differentiating
color choices
• Maintained excellent mechanical
performance after repeated steam
sterilization and harsh chemical cleaning
• Offered low MOQ with flexible supply
Transcend™ Premier Healthcare Colorants
KEY REQUIREMENTS
WHY AVIENT?
https://www.avient.com/sites/default/files/2021-07/mevopur-pharma-packaging-1-page-case-study.pdf
PHARMACEUTICAL
PACKAGING OEM
V I A L S , B O T T L E S &
C O N T A I N E R S
• Raw materials pre-tested to USP 661.1 and ICHQ3D
guidelines
• Stabilization during molding and sterilization processes for
both opaque and transparent polymer materials
• Certified formulations available globally
• Offered pre-tested raw materials and
produced in an ISO 13485 certified site,
minimizing risk across the pharmaceutical
value chain
• Delivered specialized formulated solutions
to meet stringent pharmaceutical packaging
requirements
• Provided global formulations transferrable
from our three ISO 13485 certified facilities
Mevopur™ Healthcare Concentrates
KEY REQUIREMENTS
WHY AVIENT?
https://www.avient.com/sites/default/files/2022-02/Versaflex-Handler Housing for Laparoscopic Sealer-Application snapshot.pdf
SURGICAL
DEVICE
MANUFACTURER
H A N D L E H O U S I N G F O R
L A P A R O S C O P I C S E A L E R
• Excellent adhesion onto PC/ABS
• Good aesthetics with soft touch
• RoHS, REACH and FDA compliant
• Enhanced ergonomics and functionality with
improved soft grip
• Met performance requirements for wear
resistance and colorability
• Customized a thermoplastic elastomer (TPE)
solution and had with a faster sample
response speed than competitor
Versaflex™ Overmolding Formulation
KEY REQUIREMENTS WHY AVIENT?
https://www.avient.com/sites/default/files/2022-08/reSound Bio -Swimming Goggle-Application Snapshot.pdf
AVIENT SOLUTION
SWIMMING GEAR
BRAND
S W I M G O G G L E G A S K E T A N D
N O S E B R I D G E
• Bio-content material
• Good adhesion to PC
• Flexible and comfortable to wear
• Easy to process
• Customized formulations for a transparent Shore 43A
TPE with 40% bio-based content for the gasket and a
natural 57A TPE with 30% bio-based content for the
nose bridge to meet sustainability and comfort targets
• Delivered excellent performance in order to pass strict
chlorine, brine, and QUV tests
• Offered prompt development and on-site technical
services to accelerate commercialization
KEY REQUIREMENTS
SUSTAINABILITY + SEALING
LEARN MORE
reSoundTM BIO Thermoplastic Elastomers
Copyright © 2022, Avient Corporation.
https://www.avient.com/sites/default/files/2025-03/Q4 2024 Avient Webcast Slides w Non-GAAP.pdf
EPS guidance
2025 financial guidance
▲ Further Fed rate cuts
▲ Chinese stimulus
▲ Economic recovery in Europe
▲ Continued strength in defense applications
for both military and local law enforcement
▼ Policy uncertainty and changes
▼ Persistent inflation impacting consumer spending /
slowdown of US economy
▼ Further deterioration of Europe economy
▼ FX volatility
M A C R O A S S U M P T I O N S I N F L U E N C I N G R A N G E
19Copyright © .
All Rights Reserved
2025
Avient 2024 sales
B U S I N E S S S E G M E N T S E N D M A R K E T S R E G I O N S
63%
37%
S E M
C A I
23%
20%
15%
10%
10%
8%
7%
4% 3%
Packaging
Telecom
Energy
Defense
Healthcare
Building &
construction
Transportation
Industrial
Consumer
41%
35%
18%
6%
US &
Canada
Latin America
Asia
Europe, Middle East
and Africa
20Copyright © .
All Rights Reserved
2025
Color, Additives & Inks
E N D M A R K E T S R E G I O N S
34%
21%
15%
11%
9%
8%
Packaging
Telecom 1%Energy 1%
Transportation
Industrial
Consumer
34%
37%
20%
9%
US & Canada
Latin America
Asia
Europe, Middle East
and Africa
Healthcare
Building &
Construction
21Copyright © .
https://www.avient.com/sites/default/files/2024-03/AVNT February IR Presentation_w_Non-GAAP Recs_v2.pdf
Avient corporation first quarter 2023 results
AVIENT CORPORATION
I N V E S T O R P R E S E N T A T I O N
(NYSE: AVNT)
F E B R U A R Y 2 0 2 4
D I S C L A I M E R
Forward-Looking Statements
Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
Continue fostering our Great
Place to Work® culture
Strategic Objectives
Long Term
Growth
Rates
Growth Drivers
$340
$455
$790
$1,135
2016 2018 2020 2023
$51
$84
$212
$645
2016 2018 2020 2023
$108 $113
$231 $230
2016 2018 2020 2023
$265
$358
$726 $725
2016 2018 2020 2023
8-12% 8-10% 8-10% 5%
Sustainable Solutions Composites Healthcare Asia/Emerging Regions
Profitable Growth Great Place to Work
5.4%
10.9%
16.0%
2006 2014 2023
EBITDA Margins
$0.14
$1.93
$2.36
2006 2014 2023
Adjusted EPS
TOP -T IE R S US TAINABIL IT Y P E RF ORM ANCE
AND RE COGNIT ION
Industry Sustainability Standards
ESG Ratings Performance
1
2
4
87th
94th
percentile
5
Avient CDP Score:
A-
F E B R U A R Y 1 4 , 2 0 2 4
W E B C A S T
P R E S E N T AT I O N
DR.
AS HIS H KHANDP UR
P R E S I D E N T & C E O
7
8
PORTFOLIO TRANSFORMATION
8
7%
46%
66%
87%
100%
0%
20%
40%
60%
80%
100%
2005 2010 2015 2020 2023
%
o
f A
dj
us
te
d
E
B
IT
D
A
Commodity JVs Distribution Performance Products & Solutions Specialty Businesses
Adjusted EBITDA from Specialty Applications
SUSTAINABILITY AS A GROWTH DRIVER
9
LONG-TERM REVENUE GROWTH DRIVERS
Sustainable
Solutions
Composites, Healthcare,
Asia / LATAM
Overlap
Other
60%+
Key Growth
Drivers
Total Company Revenue
Growth Drivers Long-Term Growth Rate
Sustainable Solutions 8–12%
Composites 8–10%
Healthcare 8–10%
Asia / LATAM 5%
Other 0–2%
Avient 6%
END MARKET OBSERVATIONS
( % O F C O M PA N Y S A L E S )
ENERGY
5%
DEFENSE
7%
TELECOMMUNICATIONS
4%
HEALTHCARE
7%
10
TRANSPORTATION
10%
INDUSTRIAL
16%
BUILDING &
CONSTRUCTION 9%
CONSUMER
19%
PACKAGING
23%
11
REGIONAL OBSERVATIONS
( % O F C O M PA N Y S A L E S )
11
US & Canada
Latin America
EMEA
Asia
41%
36%
18%
5%
Q 4 2 0 2 3 R E S U L T S
Q4 2023 PERFORMANCE VS.
https://www.avient.com/sites/default/files/2023-03/AVNT Q2 2022 Earnings Presentation - Website Version.pdf
Microsoft PowerPoint - AVNT Q2 2022 Earnings Presentation
AVIENT CORPORATION
S E C O N D Q U A R T E R 2 0 2 2 R E S U L T S
(NYSE: AVNT)
J U L Y 2 6 , 2 0 2 2
D I S C L A I M E R
2
Forward-Looking Statements
Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
S E C O N D Q U A R T E R 2 0 2 2
R E S U L T S
$122
$134
2021 2022
$0.87
$0.98
2021 2022
Q2 2022 PERFORMANCE
( T O TA L C O M PA N Y )
4
Sales Adjusted Operating Income
$1,235
$1,302
2021 2022
+ 5%
Adjusted EPS
+ 10% + 13%
(in millions) (in millions)
(+ 10% excluding FX) (+ 16% excluding FX) (+ 20% excluding FX)
Q2 2022 SEGMENT PERFORMANCE
5
CAI
$624
$649
Sales
($ in millions)
SEM Distribution
$86
$94
Operating Income
+ 4% + 9%
$404
$443
Sales
$24
$27
Operating Income
+ 10% + 13%
(1)
$241 $244
Sales
$37 $37
Operating Income
+ 1% Flat
(+ 10% excluding FX) (+ 16% excluding FX) (+ 6% excluding FX) (+ 3% excluding FX)
Q2 2021 $1,235 $122
Sustainable Solutions 17 7% 7
Healthcare 23 14% 5
Composites (ex Outdoor High Performance) 10 20% 4
Growth in Asia / LATAM 5 3% 1
Other 69 11% 5
Sub-total $1,359 10% $144
Outdoor High Performance Impact (9) (5)
Wage Inflation and Overtime (7)
Other Supply Chain Costs (2)
Clariant Color Integration Synergies 7
Incentives, Other Employee Costs 4
FX (48) (7)
Q2 2022 $1,302 5% $134
Q2 2022 SALES AND OPERATING INCOME
( T O TA L C O M PA N Y )
6
Sales Growth Rate
Adjusted
Operating
Income$ millions
Adjusted
EBITDA
Q2 EBITDA BRIDGE
7
Price increases more than
offsets raw material and
supply chain impacts
Q2 2021 $ 159
Demand (29)
$ millions
CAI:
Price / Mix 87
Inflation (58)
SEM:
Price / Mix 36
Inflation (24)
Distribution:
Price / Mix 45
Inflation (41)
Net Price Benefit 45
Wage Inflation and Overtime (7)
Other Supply Chain Costs (2)
Clariant Color Integration Synergies 7
Incentives, Other Employee Costs 4
FX (7)
Q2 2022 $ 170
China Lockdowns / Russia Impact $ (14)
Outdoor High Performance (5)
Transportation (5)
8
Q2 '21 Adjusted EPS 0.87$
Color, Additives and Inks 0.11
Specialty Engineered Materials 0.01
Distribution 0.03
Corporate Costs 0.01
F/X (0.05)
Segment OI 0.11$
Interest Expense 0.03
Tax Rate (0.03)
Q2 '22 Adjusted EPS 0.98$
Q2 EPS BRIDGE
Key Updates
• Provided progress on 2030 Sustainability Goals
• Emphasized commitment to U.N.
Annual Purchases
RAW MATERIAL AND SUPPLY CHAIN UPDATE
Based on 2021 purchases, excludes Distribution business
SEGMENT DATA
U.S. & Canada
50%
EMEA
25%
Asia
16%
Latin America
9%
2021 SEGMENT, END MARKET AND GEOGRAPHY
GEOGRAPHY REVENUESEGMENT FINANCIALS
Consumer
23%
Packaging
19%
Industrial
16%
Building and
Construction
10%
Telecommunications
4%
Energy
2%
END MARKET REVENUE
(1) Total company sales and adjusted EBITDA of $4,819M and $581M, respectively, include intercompany sales eliminations and corporate costs
$2,402M
$409M
$919M
$164M
$1,631M
$94M
Sales EBITDA
Distribution
Specialty Engineered Materials
Color Additives and Inks
$581M$4,819M
(1)
Transportation
11%
Healthcare
15%
24
Packaging
34%
Consumer
21%
Healthcare
8%
Industrial
16%
Building &
Construction
10%
Transportation
9%
Energy
1% Telecommunications
1%
C O L O R , A D D I T I V E S & I N K S
2 0 2 1 R E V E N U E | $ 2 . 4 B I L L I O N
US & Canada
32%
EMEA
40%
Asia
21%
Latin America
7%
END MARKET REGION
25
All charts reflect 2021 financials
S P E C I A L T Y E N G I N E E R E D M A T E R I A L S
Consumer
27%
Healthcare
10%
Packaging
7%
Telecommunications
16%
Transportation
11%
Industrial
11%
Building &
Construction
11%
Energy
7%
2 0 2 1 R E V E N U E | $ 9 1 9 M I L L I O N
END MARKET
US & Canada
55%
EMEA
25%
Asia
20%
REGION
26
All charts reflect 2021 financials
D I S T R I B U T I O N
Healthcare
26%
Consumer
23%
Packaging
5%
Industrial
20%
Transportation
16%
Building and
Construction
8%
Energy
1%
Telecommunications
1%
US & Canada
80%
Asia
3%
Latin
America
17%
END MARKET REGION
K E Y S U P P L I E R S
2 0 2 1 R E V E N U E | $ 1 . 6 B I L L I O N
27
All charts reflect 2021 financials
T O T A L C O M P A N Y R E G I O N A L S A L E S
B Y E N D M A R K E T
Packaging
30%
Consumer
26%Healthcare
13%
Industrial
14%
Building &
Construction
5%
Telecommunications
2% Energy
2%
Asia
(16% of sales)
Transportation
8%
Packaging
32%
Consumer
13%
Healthcare
5%
Industrial
17%
Building &
Construction
12%
Telecommunications
5%
Energy
4%
EMEA
(25% of sales)
Transportation
12%
28
Consumer
25%
Healthcare
19%
Packaging
10%
Industrial
17%
Building &
Construction
10%
Telecommunications
4%
Energy
2%
US &
Canada
(50% of sales)
Transportation
13%
Packaging
38%
Consumer
33%
Healthcare
8%
Industrial
10%
Building &
Construction
5%
Telecommunications
1%
LATAM
(9% of sales)
Transportation
5%
All charts reflect 2021 financials
Reconciliation of Non-GAAP Financial Measures
(Unaudited)
(Dollars in millions, except for per share data)
Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders
and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special
items, to assess performance and facilitate comparability of results.
https://www.avient.com/sites/default/files/2020-07/case-study-one-pager-gravi-tech-luxury-closures-spanish.pdf
P R O D U C T O R L Í D E R D E
TA P O N E S PA R A B E B I DA S
A L C O H Ó L I C A S
T A P O N E S D E L U J O
• Se sustituye el metal al mismo tiempo que se ofrece
aspecto y sensación metálicos
• Personalización de densidad y color
• Procesamiento sencillo
• Cumplimiento con las normas de la FDA
• El metal se sustituye con un compuesto
plástico de densidad modificada para
mantener una percepción de alta calidad
• Se redujo al mínimo la aparición de
desportilladuras por el desgaste cotidiano,
que supera al metal porque permite hacer
coincidir el interior de la tapa con los
colores de revestimiento metalizado
• Permitió al cliente introducir sus tapones
de lujo en un nuevo segmento del mercado
Formulación de densidad modificada Gravi-
Tech™
REQUERIMIENTOS CLAVE
¿POR QUÉ AVIENT?
https://www.avient.com/sites/default/files/2021-01/mevopur-laser-welding-for-ivd-case-study-brief.pdf
G E N O M I C D I AG N O S T I C
D E V I C E M A N U FAC T U R E R
I N - V I T R O D I A G N O S T I C ( I V D ) D E V I C E
MEVOPURTM Laser-Transmitting and Laser-Absorbing
Pre-color Solution
AV I E N T S O L U T I O N
• Customized solutions - Quality-by-Design (QdB) approach
• Optimized pigment / additive selection – good distribution in
final part minimizes welding failure
• Mitigated contamination and extractable risk on incoming raw
material with control based on fingerprinting
• Ensured uninterrupted supply from multiple ISO13485-2016
certified sites
• Minimized risk of change with change control agreements
W H Y AV I E N T
K E Y R E Q U I R E M E N T S
P R O D U C T I V I T Y & Q U A L I T Y
• Good weldability, low rejection rate
• Solutions in wide range of polymers, colors and
transparency
• Pre-tested ingredients to biocompatibility and
extractable metals
L E A R N M O R E
https://www.avient.com/products/polymer-additives/performance-enhancement-additives/mevopur-functional-additives